6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01270711 (ClinicalTrials.gov)	November 2010	9/12/2010	Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)	Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)	Parkinson's Disease;Hyperprolactinemia	Drug: Study Drug	Pfizer	NULL	Completed	N/A	N/A	All	22014	N/A	NULL
2	EUCTR2005-001006-12-CZ (EUCTR)	06/09/2006	24/08/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ...	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- ...	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Czech Republic;Austria;Germany;Italy
3	EUCTR2005-001006-12-AT (EUCTR)	02/04/2006	28/02/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ...	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- ...	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	Germany;Czech Republic;Italy;Austria
4	EUCTR2005-001006-12-DE (EUCTR)	09/03/2006	05/09/2006	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the effic ...	Patients with advanced Parkinson’s disease with motor fluctuations and OFF” periods refractory to co ...	Product Name: Lisparin INN or Proposed INN: Lisuride Hydrogenmaleate Other descriptive name: 3- (9,10- ...	Axxonis Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Czech Republic;Austria;Germany;Italy
5	EUCTR2004-001485-41-GB (EUCTR)	26/07/2005	21/06/2005	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see excl ...	Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: carbidopa /levodopa Trade Name: Cabaser Pr ...	Institute for Neurodegenerative Disorders	NULL	Not Recruiting			Female: yes Male: yes	120		United Kingdom;Spain
6	EUCTR2004-001485-41-ES (EUCTR)	28/04/2005	30/01/2006	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see excl ...	Trade Name: SINEMET Product Name: carbodopa/levadopa INN or Proposed INN: CARBODOPA LEVADOPA Trade Name ...	Institute for Neurodegenerative Disorders	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120		United Kingdom;Spain
7	EUCTR2004-001485-41-AT (EUCTR)	20/04/2005	16/03/2005	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	A single-blinded assessment of the short-term effects of cabergolinevs. carbidopa/levodopa on SPECT ...	Approximately 120 recently diagnosed/early Parkinson’s disease subjects, who are untreated (see excl ...	Trade Name: Sinemet Product Name: Sinemet INN or Proposed INN: carbidopa /levodopa Trade Name: Cabaseril ...	Institute for Neurodegenerative Disorders	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120		Spain;Austria;United Kingdom
8	EUCTR2004-002650-59-GB (EUCTR)	03/02/2005	30/06/2005	A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching sub ...	A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching sub ...	Idiopathic Parkinson's disease	Product Name: rotigotine Product Code: SPM 962 INN or Proposed INN: rotigotine	SCHWARZ BIOSCIENCES	NULL	Not Recruiting			Female: yes Male: yes	130	Phase 3	United Kingdom
9	NCT00153972 (ClinicalTrials.gov)	February 2005	7/9/2005	Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease	Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression ...	Parkinson's Disease	Drug: Cabergoline;Drug: Levodopa	Technische Universität Dresden	Pfizer	Completed	40 Years	85 Years	Both	39	Phase 4	Germany
10	NCT00129181 (ClinicalTrials.gov)	January 2005	9/8/2005	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Pa ...	A Single-blinded Assessment of the Short-term Effects of Cabergolinevs. Carbidopa/Levodopa on SPECT ...	Parkinson Disease;Parkinsonian Syndrome	Drug: cabergoline;Drug: carbidopa /levodopa;Procedure: DATscan and SPECT imaging	Institute for Neurodegenerative Disorders	Pfizer;GE Healthcare	Completed	40 Years	N/A	Both	30	N/A	Austria;Germany;Italy;Spain;United Kingdom

First Previous1 2Next Last